Literature DB >> 25633245

Temporal gene expression in the hippocampus and peripheral organs to endotoxin-induced systemic inflammatory response in caspase-1-deficient mice.

Claudio Alberto Mastronardi1, Gilberto Paz-Filho, Martina Zanoni, Nicolas Molano-González, Mauricio Arcos-Burgos, Julio Licinio, Ma-Li Wong.   

Abstract

OBJECTIVES: Caspase-1 (casp1), a key protease involved in the systemic inflammatory response syndrome (SIRS), controls the brain expression of a set of eight genes: Nos2 and Ptgs2 (nitric oxide synthase 2 and prostaglandin-endoperoxide synthase 2, two inducible enzymes), Cxcl1 and Cxcl10 (C-X-C motif chemokine ligand 1 and ligand 10), Tgtp and Gbp2 (T cell-specific GTPase 1 and guanylate-binding protein 2, two GTPases), Adamts1 (a disintegrin-like and metallopeptidase with thrombospondin type 1 motif, 1, a metalloprotease) and Il1rn (interleukin-1 receptor antagonist). Our objective was to ascertain whether casp1 also controlled the peripheral expression of these genes and, if so, to compare their central versus peripheral patterns of gene expression in immune and endocrine tissues during SIRS.
METHODS: Wild-type (wt) and casp1 knockout (casp1(-/-)) mice were injected with either saline or a high dose of endotoxin/lipopolysaccharide (LPS; 800 μg/mice i.p.). Saline-injected mice were immediately euthanized after injection, whereas LPS-injected mice were sacrificed 6 and 12 h after LPS administration. Hippocampal, splenic and adrenal gene expressions were determined by real-time PCR.
RESULTS: Overall, casp1(-/-) mice showed a lower inflammatory response than wt mice. The expression levels of powerful proinflammatory factors such as Nos2 and Ptgs2 was reduced in casp1(-/-) mice. Moreover, a hierarchical clustering analysis aimed at studying patterns of gene coexpression revealed large alterations in the hippocampal pattern of casp1(-/-) mice. Surprisingly, the expression of Adamts1 was increased in the hippocampus and adrenals of casp1(-/-) mice.
CONCLUSIONS: The resilience of casp1(-/-) mice to SIRS lethality is associated with a lower inflammatory response, loss of hippocampal gene coexpression patterns, and increased hippocampal Adamts1 gene expression. The latter might be beneficial for casp1(-/-) mice, since ADAMTS1 is likely to play a role in neuronal plasticity. The mechanisms described here may help the development of either novel biomarkers or therapeutic targets against SIRS/sepsis.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633245      PMCID: PMC4710542          DOI: 10.1159/000368310

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  50 in total

Review 1.  The pathophysiology and treatment of sepsis.

Authors:  Richard S Hotchkiss; Irene E Karl
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

2.  Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system.

Authors:  C A Mastronardi; W H Yu; S McCann
Journal:  Neuroimmunomodulation       Date:  2001       Impact factor: 2.492

3.  Guanylate binding proteins promote caspase-11-dependent pyroptosis in response to cytoplasmic LPS.

Authors:  Danielle M Pilla; Jon A Hagar; Arun K Haldar; Ashley K Mason; Daniel Degrandi; Klaus Pfeffer; Robert K Ernst; Masahiro Yamamoto; Edward A Miao; Jörn Coers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-08       Impact factor: 11.205

4.  Lipopolysaccharide-induced leptin release is neurally controlled.

Authors:  C A Mastronardi; W H Yu; V K Srivastava; W L Dees; S M McCann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  Mice deficient in interleukin-1beta converting enzyme resist anorexia induced by central lipopolysaccharide.

Authors:  J H Yao; S M Ye; W Burgess; J F Zachary; K W Kelley; R W Johnson
Journal:  Am J Physiol       Date:  1999-11

6.  Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis.

Authors:  M L Wong; B Xie; N Beatini; P Phu; S Marathe; A Johns; P W Gold; E Hirsch; K J Williams; J Licinio; I Tabas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

7.  ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function.

Authors:  T Shindo; H Kurihara; K Kuno; H Yokoyama; T Wada; Y Kurihara; T Imai; Y Wang; M Ogata; H Nishimatsu; N Moriyama; Y Oh-hashi; H Morita; T Ishikawa; R Nagai; Y Yazaki; K Matsushima
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 8.  Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Endocrinology       Date:  2002-05       Impact factor: 4.736

9.  Lipopolysaccharide-induced leptin release is not mediated by nitric oxide, but is blocked by dexamethasone.

Authors:  C A Mastronardi; W H Yu; V Rettori; S McCann
Journal:  Neuroimmunomodulation       Date:  2000       Impact factor: 2.492

10.  NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide.

Authors:  R G Kilbourn; S S Gross; A Jubran; J Adams; O W Griffith; R Levi; R F Lodato
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

View more
  2 in total

1.  Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement.

Authors:  Andrea Stojakovic; Gilberto Paz-Filho; Mauricio Arcos-Burgos; Julio Licinio; Ma-Li Wong; Claudio A Mastronardi
Journal:  Mol Neurobiol       Date:  2016-06-29       Impact factor: 5.590

Review 2.  Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma.

Authors:  Antonio Inserra; Claudio Alberto Mastronardi; Geraint Rogers; Julio Licinio; Ma-Li Wong
Journal:  Mol Neurobiol       Date:  2018-10-10       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.